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A 56-year-old Korean woman presented with decreased visual acuity of the right eye. She had a history of two pho-
todynamic therapy treatments for choroidal neovascularization (CNV) due to angioid streaks in her left eye with cen-
tral scarring and low visual acuity. She was diagnosed with subfoveal CNV due to angioid streaks in her right eye 
and treated with six intravitreal bevacizumab (1.25 mg / 0.05 mL) injections over one year. Best corrected visual 
acuity improved from 20 / 125 at baseline to 20 / 50 at the final visit. The area of CNV had changed into a fibrotic scar 
by the final visit, and fluorescein angiography and indocyanine green angiography revealed no evidence of leakage. 
Optical coherence tomography showed that central macular thickness decreased from 311 µm at baseline to 203 
µm with complete resolution of subretinal and intraretinal fluid at the final visit. Intravitreal bevacizumab for CNV as-
sociated with angioid streaks prevented the progression of disease and resulted in the improvement of visual acuity 
after one year of follow-up in our patient.
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Angioid streaks are irregularly radiating gray lines that ex-
tend from the area around the optic disc. Angioid streaks re-
sult from rupture or dehiscence of a calcified and brittle 
Bruch’s membrane between the retinal pigment epithelium 
and the choroid. Angioid streaks may be idiopathic, but are 
associated with systemic diseases in about half of the pa-
tients, such as Paget’s disease, pseudoxanthoma elasticum, 
Ehlers-Danlos syndrome or sickle cell anemia [1]. Choroidal 
neovascularization (CNV) is the major cause of vision loss 
associated with angioid streaks. CNV occurs in 72% to 86% 
of eyes with angioid streaks, is often bilateral, and has poor 
prognosis if left untreated [2-4].
 
Laser photocoagulation has been widely used to treat jux-
tafoveal and extrafoveal CNV. However, a high rate of re-
currence and laser-induced scar progression toward the fovea 
has been reported [5,6].
 Subfoveal lesions have been treated 
with photodynamic therapy (PDT) with verteporfin. Published 
reports of PDT have documented contradictory results. Some 
authors present short-term benefits of PDT in the treatment 
of CNV secondary to angioid streaks and suggest that PDT 
may limit or delay visual damage [7,8]. However, the long-term 
results of PDT are disappointing and include enlargement of 
the CNV lesion to a disciform scar and associated visual loss 
[9-12].
In recent years, an anti-VEGF agent has been widely used 
as a new treatment for CNV. Intravitreal bevacizumab (Genentech, 
South San Francisco, CA, USA) has been effective in the 
treatment of CNV secondary to age-related macular degener-
ation and pathologic myopia [13,14]. To date, the results of 
intravitreal bevacizumab for the treatment of CNV due to 
angioid streaks have been reported in case series with most 
eyes maintaining or even improving in visual acuity [15-18]. 
However, most of these reports have no indocyanine green 
angiography (ICGA) data or are limited to short term follow-up. 
In this case report, we present the clinical course, including 
ICGA results, of a patient with subfoveal CNV secondary to 
angioid streaks treated with intravitreal bevacizumab, who 
exhibited disease progression despite previous PDT and was 
followed up for 12 months.
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Fig. 1. Early (A) and late (B) phase of fluorescein angiography 
(FAG) showing previous juxtafoveal classic choroidal neo-
vascularization (CNV) that increased and progressed into the sub-
foveal area despite a photodynamic therapy treatment. (C) Early 
phase of indocyanine green angiography showing a more distinct 
margin of the subfoveal CNV lesion than FAG. (D) Late phase of 
indocyanine green angiography showing a peau d’orange appear-
ance in the posterior pole with hyperfluorescent angioid streaks 
connected to the CNV lesion in late phase, which were not seen in 
FAG. (E) Optical coherence tomography showing a hyperreflective
subfoveal choroidal neovascular membrane with cystoid macular 
edema and neurosensory serous detachment.
sion in the right eye of two months duration. She received a 
PDT treatment for CNV with angioid streaks in her right eye 
at another medical center one month before presentation. She 
complained of deteriorated visual acuity of the right eye after 
PDT treatment. She also had a history of two PDT treatments 
for CNV with angioid streaks in her other eye at another 
medical center four years prior. She was diagnosed with 
pseudoxanthoma elasticum by skin biopsy at that time. 
Ocular examination revealed a best corrected visual acuity 
(BCVA) of 20 / 125 in the right eye and 20 / 800 in the left eye 
at the initial visit. Fundus examination revealed peripapillary 
angioid streaks in both eyes, a grayish subfoveal lesion with 
mild subretinal exudates in the right eye, and a large disci-
form scar at the macula in the left eye. Unfortunately, a color 
fundus photograph from the initial visit was not available. 
Fluorescein angiography (FAG) and ICGA were performed 
with a Heidelberg retina angiograph using a scanning laser 
ophthalmoscope after an intravenous injection of 5 mL of 
10% fluorescein sodium (Fluorescite Injection; Alcon, Fort 
Worth, TX, USA) and 25 mg of indocyanine green (Dong In 
Dang Pharm., Siheung, Korea) dissolved in 10 mL of sterile 
water. The last images were obtained at least 30 minutes after 
the injection of the dye. FAG showed subfoveal classic CNV 
associated with leakage and peripapillary hyperfluorescence 
corresponding to the angioid streaks in the right eye. ICGA 
showed a more distinct margin of subfoveal CNV in early 
phase than FAG and a peau d’orange appearance in the poste-
rior pole with hyperfluorescent angioid streaks connected to 
the CNV lesion in late phase, which were not seen in FAG. 
Both FAG and ICGA of the right eye revealed an increased 
CNV lesion size and progression to the center of the fovea 
despite the previous PDT treatment that was performed at an-
other medical center. Optical coherence tomography (OCT) 
was performed using OCT 3 (Carl Zeiss Meditech, Dublin, 
CA, USA), and a central macular thickness (CMT) was ob-
tained using a fast macular map protocol. OCT scans of the 
right eye revealed a hyperreflective subfoveal choroidal neo-
vascular membrane with cystoid macular edema and neuro-
sensory serous detachment. CMT was 311 µm in the right 
eye (Fig. 1).
Follow-up visits were carried out one week after intra-
vitreal bevacizumab injection and then monthly for 12 
months. For each visit, the BCVA using a Snellen chart, in-
traocular pressure and any complications were assessed. 
FAG, ICGA and OCT were performed one month after each 
injection to evaluate the effect of the intravitreal bev-
acizumab injection. Additional treatment was administered 
when the lesion exhibited persistent leakage or growth on 
FAG and ICGA and when the presence of subretinal or intra-
retinal fluid on OCT combined with decreasing visual acuity 
was detected.
After four consecutive monthly intravitreal injections of 
bevacizumab (1.25 mg / 0.05 mL) in the right eye, BCVA im-
proved from 20 / 125 at baseline to 20 / 50 at four months. A 
color fundus photograph at this time indicated resolution of 
subretinal exudates and a contracted subfoveal lesion in the 
right eye. FAG and ICGA revealed a minimal amount of per-
sistent leakage at one, two and three months, although CNV 
size and leakage decreased markedly. Both FAG and ICGA 
indicated that there was no leakage of CNV and the greatest 
linear diameter of the lesion decreased from 1,280 µm at 
baseline to 730 µm at 4 months. However, ICGA displayed a 
more distinct margin of CNV than FAG despite the presence 
of diffuse pigment migration at the fovea. OCT showed that 
CMT decreased from 311 µm at baseline to 210 µm and was 
absent of subretinal fluid at 4 months. Nevertheless, com-
plete resolution of intraretinal fluid on OCT did not occur by 
4 months. 
BCVA decreased from 20 / 50 at 4 months to 20 / 63 at 8 
months. A color fundus photograph exposed a newly devel-






Fig. 2. At 12 months after a total of six intravitreal bevacizumab injections. (A) Color fundus photograph showing resolution of subretinal hem-
orrhage and exudates and the contracted subfoveal lesion. Early (B) and late (C) phase of fluorescein angiography and early (E) and late (F) 
phase of indocyanine green angiography revealing leakage resolution. (D) Optical coherence tomography showing a decrease in central mac-
ular thickness and absence of intraretinal fluid with normal foveal contour. 
and ICGA revealed that a new CNV lesion developed at the 
superior margin of the previous lesion at 8 months. CMT in-
creased from 210 µm at 4 months to 233 µm at 8 months. 
Therefore, two additional, consecutive, monthly intra-
vitreal bevacizumab injections were required. After a total of 
six intravitreal bevacizumab injections, BCVA improved 
from 20 / 125 at baseline to 20 / 50 at the final visit. A color 
fundus photograph showed that the CNV area had changed 
into a contracted fibrotic scar with complete resolution of 
subretinal hemorrhage and exudates at the final visit. FAG 
and ICGA revealed no angiographic evidence of leakage. 
OCT demonstrated CMT decreased from 311 µm at baseline 
to 203 µm with complete resolution of intraretinal fluid at the 
final visit (Fig. 2). No injection-related complications or 
drug-related side effects were observed.
Discussion
In the present study, PDT was performed for CNV due to 
angioid streaks in the right eye of the patient at another medi-
cal center one month before presentation. However, visual 
acuity deteriorated after PDT, and juxtafoveal CNV pro-
gressed to the subfoveal area with lesion enlargement. In ad-
dition, her left eye revealed disciform scarring with low visu-
al acuity despite two PDT treatments. These findings corre-
spond to earlier results that reported disease progression with 
a decrease in visual acuity after PDT for CNV in angioid 
streaks [9-12]. However, visual acuity improved with no an-
giographic evidence of leakage and a decrease in CMT at 
four months after four consecutive monthly intravitreal bev-
acizumab injections. These findings correspond with earlier 
studies reporting that intravitreal bevacizumab stabilized or 
improved visual acuity with favorable anatomic outcomes in 
either naïve eyes or eyes that had failed previous PDT treat-
ment [15,16]. 
A new CNV lesion was noted at the superior margin of the 
previous CNV area at eight months (four months after the 
last intravitreal bevacizumab injection) in the present study. 
Fortunately, visual acuity increased with no leakage on an-
giography or flattening of retinal edema on OCT after two 
additional consecutive monthly intravitreal bevacizumab 
injections. 
These results are consistent with long term follow-up stud-
ies that reported that the mean interval between retreatments 
was about four months and intravitreal bevacizumab in-
jections had to be repeated in all patients [17,18]. 
In a retrospective study of nine eyes in six patients, 
Wiegand et al. [17] reported that visual acuity stabilized or 
improved in eight eyes (88.8%) with a reduction in retinal 
thickness in all eyes after a mean follow-up of 19 months. In 
a prospective study with eleven patients, Neri et al. [18] re-
ported that visual acuity stabilized or improved with reduced 
or stable CNV size in all eyes at 20 months. These long term 
follow-up results suggest that early retreatment may ensure 
favorable functional and anatomical outcomes and prevent 
disease progression. JW Lee, et al. CNV in Angioid Streaks Treated with Bevacizumab
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Anatomical improvement was associated with a con-
comitant increase in visual acuity in the present study. Our 
result are consistent with previous studies reporting improve-
ment of functional results correlated with a decrease in the 
greatest lesion height on OCT [15,16]. In addition, the visual 
acuity deterioration was followed by an increase of CMT in 
the present study. Therefore, regular follow-up with visual 
acuity testing and close observation of the macula using OCT 
may inform decisions for early intervention in order to pre-
vent disease progression.
In contrast to previous therapeutic regimens, such as laser 
photocoagulation and PDT, that often result in disciform 
scarring and irreversible loss of function of the retinal pig-
ment epithelium (RPE) and overlying retina [10], intravitreal 
bevacizumab injection in the present study resulted in im-
provement of visual and anatomic outcomes without scar 
formation. Intravitreal bevacizumab injection may have anti-
exudative and antiproliferative effects while preserving the 
RPE and overlying retina [15,19].
The results obtained from our patient indicate that intra-
vitreal bevacizumab for CNV associated with angioid streaks 
may prevent the progression of disease and result in the im-
provement of visual acuity. 
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